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Purpose
There are great needs for innovative pharmacotherapies
in combination with clinical tests to identify asympto-
matic children at risk of developing scoliosis and symp-
tomatic ones to predict who may be at risk of scoliotic
curve progression. Early detection of scoliosis is critical
to broaden the range of treatment options and increases
effectiveness. Currently, there are no FDA cleared “pre-
symptomatic” diagnostic tests available for assessing
scoliosis in paediatric patients. We have developed a
cell-based screening assay for the early diagnosing of
presymptomatic subjects and a biochemical blood test
for asymptomatic individuals and patients at different
disease stage.
Methods
Peripheral blood samples for AIS patients, asymptomatic
children and control subjects were collected in blood
collection tubes containing EDTA and then centrifuged
on a Ficoll-Plaque solution to obtain peripheral blood
mononuclear cells (PBMCs) and plasma. Gi-coupled
receptor signal transduction was measured by cellular
dielectric spectroscopy (CDS) in presence of varying
concentration of melatonin or other ligands. Plasma
concentrations of OPN and sCD44 were measured by
ELISA methods adapted to be performed on a robotic
platform.
Results
In a cross-sectional clinical study, we have shown that
mean plasma OPN levels were significantly increased in
AIS patients (n=320) and correlated with disease severity
with average values of 743±326 and 975±389 ng/ml for
moderate and severe spinal deformities, respectively,
when compared to the healthy control group (568±
216 ng/ml; n=120). Elevated plasma OPN levels were
also found in the asymptomatic at-risk group (871±
387 ng/ml; n=87), suggesting that these changes precede
scoliosis onset. Data obtained using PBMCs revealed a
melatonin signaling impairment only in IS patients at
different disease stages when compared to healthy con-
trols showing a high specificity (100%) and sensitivity
( 1 0 0 % ) .R i s ko fd e v e l o p i n gascoliosis in asymptomatic
children was determined by CDS in 33% of asympto-
matic children at risk.
Conclusion
B o t ht e s t sh a v eau n i q u ea d v a n t a g es i n c et h e yc a nb e
performed without any prior knowledge of mutations in
any defective genes causing AIS. The standard of care
for scoliosis has not changed in any significant manner
in decades. Patients today are treated in a substantially
similar manner to those twenty or thirty years ago –
observation, bracing, and fusion as a last resort. Our
diagnostic blood-assay may have the potential to change
the way scoliosis patients are diagnosed and treated.
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